Literature DB >> 26385352

Antileukotrienes in upper airway inflammatory diseases.

Cemal Cingi1,2, Nuray Bayar Muluk3, Kagan Ipci4, Ethem Şahin5.   

Abstract

Leukotrienes (LTs) are a family of inflammatory mediators including LTA4, LTB4, LTC4, LTD4, and LTE4. By competitive binding to the cysteinyl LT1 (CysLT1) receptor, LT receptor antagonist drugs, such as montelukast, zafirlukast, and pranlukast, block the effects of CysLTs, improving the symptoms of some chronic respiratory diseases, particularly bronchial asthma and allergic rhinitis. We reviewed the efficacy of antileukotrienes in upper airway inflammatory diseases. An update on the use of antileukotrienes in upper airway diseases in children and adults is presented with a detailed literature survey. Data on LTs, antileukotrienes, and antileukotrienes in chronic rhinosinusitis and nasal polyps, asthma, and allergic rhinitis are presented. Antileukotriene drugs are classified into two groups: CysLT receptor antagonists (zafirlukast, pranlukast, and montelukast) and LT synthesis inhibitors (5-lipoxygenase inhibitors such as zileuton, ZD2138, Bay X 1005, and MK-0591). CysLTs have important proinflammatory and profibrotic effects that contribute to the extensive hyperplastic rhinosinusitis and nasal polyposis (NP) that characterise these disorders. Patients who receive zafirlukast or zileuton tend to show objective improvements in, or at least stabilisation of, NP. Montelukast treatment may lead to clinical subjective improvement in NP. Montelukast treatment after sinus surgery can lead to a significant reduction in eosinophilic cationic protein levels in serum, with a beneficial effect on nasal and pulmonary symptoms and less impact in NP. Combined inhaled corticosteroids and long-acting β-agonists treatments are most effective for preventing exacerbations among paediatric asthma patients. Treatments with medium- or high-dose inhaled corticosteroids, combined inhaled corticosteroids and LT receptor antagonists, and low-dose inhaled corticosteroids have been reported to be equally effective. Antileukotrienes have also been reported to be effective for allergic rhinitis.

Entities:  

Keywords:  Allergic rhinitis; Antileukotriene drugs; Asthma; Chronic rhinosinusitis with nasal polyposis; Leukotrienes

Mesh:

Substances:

Year:  2015        PMID: 26385352     DOI: 10.1007/s11882-015-0564-7

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  88 in total

Review 1.  The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis.

Authors:  R A Simon
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma.

Authors:  J Adamjee; Y-J Suh; H-S Park; J-H Choi; J F Penrose; B K Lam; K F Austen; A M Cazaly; S J Wilson; A P Sampson
Journal:  J Pathol       Date:  2006-07       Impact factor: 7.996

3.  Antileukotrienes in rhinosinusitis and nasal polyposis.

Authors:  Isam Alobid; Sara Cardelús; Cèsar Picado; Joaquim Mullol
Journal:  Expert Rev Clin Immunol       Date:  2008-05       Impact factor: 4.473

Review 4.  Antileukotrienes, asthma pathogenesis and the pharmaceutical industry.

Authors:  P M O'Byrne
Journal:  CMAJ       Date:  1999-01-26       Impact factor: 8.262

5.  Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis.

Authors:  E M Minshall; L Cameron; F Lavigne; D Y Leung; D Hamilos; E A Garcia-Zepada; M Rothenberg; A D Luster; Q Hamid
Journal:  Am J Respir Cell Mol Biol       Date:  1997-12       Impact factor: 6.914

Review 6.  [Recent advances in allergic rhinitis].

Authors:  Meijun Liang; Rui Xu; Geng Xu
Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi       Date:  2015-02

7.  Clinical practice guideline: Allergic rhinitis.

Authors:  Michael D Seidman; Richard K Gurgel; Sandra Y Lin; Seth R Schwartz; Fuad M Baroody; James R Bonner; Douglas E Dawson; Mark S Dykewicz; Jesse M Hackell; Joseph K Han; Stacey L Ishman; Helene J Krouse; Sonya Malekzadeh; James Whit W Mims; Folashade S Omole; William D Reddy; Dana V Wallace; Sandra A Walsh; Barbara E Warren; Meghan N Wilson; Lorraine C Nnacheta
Journal:  Otolaryngol Head Neck Surg       Date:  2015-02       Impact factor: 3.497

8.  Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa.

Authors:  H Shirasaki; E Kanaizumi; K Watanabe; T Matsui; J Sato; S Narita; M Rautiainen; T Himi
Journal:  Clin Exp Allergy       Date:  2002-07       Impact factor: 5.018

9.  GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP).

Authors:  D L Hamilos; D Y Leung; D P Huston; A Kamil; R Wood; Q Hamid
Journal:  Clin Exp Allergy       Date:  1998-09       Impact factor: 5.018

10.  Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment.

Authors:  Joel Hay; Mehul Jhaveri; Muralikrishna Tangirala; Michael Kaliner
Journal:  Allergy Asthma Proc       Date:  2009 Nov-Dec       Impact factor: 2.587

View more
  10 in total

1.  Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease.

Authors:  Saangyoung E Lee; Douglas R Farquhar; Katherine N Adams; Maheer M Masood; Brent A Senior; Brian D Thorp; Adam M Zanation; Charles S Ebert
Journal:  Am J Rhinol Allergy       Date:  2019-09-04       Impact factor: 2.467

Review 2.  A Review of Classification Schemes for Chronic Rhinosinusitis with Nasal Polyposis Endotypes.

Authors:  Steven K Dennis; Kent Lam; Amber Luong
Journal:  Laryngoscope Investig Otolaryngol       Date:  2016-09-09

3.  Inhibition of 5-lipoxygenase inhibitor zileuton in high-fat diet-induced nonalcoholic fatty liver disease progression model.

Authors:  Kuifen Ma; Yihe Chen; Xingguang Liang; Jing Miao; Qingwei Zhao
Journal:  Iran J Basic Med Sci       Date:  2017-11       Impact factor: 2.699

4.  Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo.

Authors:  Remco van Dijk; Sem J Aronson; Dirk R de Waart; Stan F van de Graaf; Suzanne Duijst; Jurgen Seppen; Ronald Oude Elferink; Ulrich Beuers; Piter J Bosma
Journal:  Sci Rep       Date:  2017-05-10       Impact factor: 4.379

5.  Inhibition of 5-lipoxygenase alleviates graft-versus-host disease.

Authors:  Barbara Maximino Rezende; Rayssa Maciel Athayde; William Antônio Gonçalves; Carolina Braga Resende; Priscila Teles de Tolêdo Bernardes; Denise Alves Perez; Lísia Esper; Alesandra Côrte Reis; Milene Alvarenga Rachid; Marina Gomes Miranda E Castor; Thiago Mattar Cunha; Fabiana Simão Machado; Mauro Martins Teixeira; Vanessa Pinho
Journal:  J Exp Med       Date:  2017-09-25       Impact factor: 14.307

6.  Evaluation of Montelukast for the Treatment of Children With Japanese Cedar Pollinosis Using an Artificial Exposure Chamber (OHIO Chamber).

Authors:  Kazuhiro Hashiguchi; Kimihiro Okubo; Yoichi Inoue; Hirotaka Numaguchi; Kumi Tanaka; Nobuyuki Oshima; Anish Mehta; Chisato Nishida; Itori Saito; George Philip
Journal:  Allergy Rhinol (Providence)       Date:  2018-07-13

7.  Relationship Between Gender and the Effectiveness of Montelukast: An Italian/Danish Register-Based Retrospective Cohort Study.

Authors:  Maurizio Sessa; Annamaria Mascolo; Bruno D'Agostino; Antonio Casciotta; Vincenzo D'Agostino; Fausto De Michele; Mario Polverino; Giuseppe Spaziano; Mikkel Porsborg Andersen; Kristian Kragholm; Francesco Rossi; Christian Torp-Pedersen; Annalisa Capuano
Journal:  Front Pharmacol       Date:  2018-08-02       Impact factor: 5.810

8.  Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells.

Authors:  Christopher Wolf; Sonja Smith; Sjoerd J L van Wijk
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

Review 9.  Research Advances in the Treatment of Allergic Rhinitis by Probiotics.

Authors:  Peng Liu; Tianyong Hu; Chenglin Kang; Jiangqi Liu; Jin Zhang; Hong Ran; Xianhai Zeng; Shuqi Qiu
Journal:  J Asthma Allergy       Date:  2022-10-07

10.  HIV X4 Variants Increase Arachidonate 5-Lipoxygenase in the Pulmonary Microenvironment and are associated with Pulmonary Arterial Hypertension.

Authors:  Brandy E Wade; Kristi M Porter; Sharilyn Almodovar; Justin M Smith; Robert A Lopez-Astacio; Kaiser Bijli; Bum-Yong Kang; Sushma K Cribbs; David M Guidot; Deborah Molehin; Bryan K McNair; Laura Pumarejo-Gomez; Jaritza Perez Hernandez; Ethan A Salazar; Edgar G Martinez; Laurence Huang; Cari F Kessing; Edu B Suarez-Martinez; Kevin Pruitt; Priscilla Y Hsue; William R Tyor; Sonia C Flores; Roy L Sutliff
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.